Publicaciones en colaboración con investigadores/as de University Hospital of Bern (34)

2024

  1. Clinical and genetic characteristics of a large international cohort of individuals with rare NR5A1/SF-1 variants of sex development

    eBioMedicine, Vol. 99

  2. Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?

    Cancers, Vol. 16, Núm. 13

  3. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

    European urology oncology, Vol. 7, Núm. 3, pp. 462-468

  4. The “Woundosome” Concept and Its Impact on Procedural Outcomes in Patients With Chronic Limb-Threatening Ischemia

    Journal of Endovascular Therapy

2023

  1. ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

    Clinical and Translational Radiation Oncology, Vol. 43

  2. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer

    Clinical and Translational Radiation Oncology, Vol. 41

  3. Genetic reanalysis of patients with a difference of sex development carrying the NR5A1/SF-1 variant p.Gly146Ala has discovered other likely disease-causing variations

    PloS one, Vol. 18, Núm. 7, pp. e0287515

  4. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology

  5. The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders

    Brain, Vol. 146, Núm. 8, pp. 3273-3288

2022

  1. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

    Radiotherapy and Oncology, Vol. 172, pp. 1-9

2021

  1. The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

    European Urology Focus

2020

  1. Acute severe paediatric asthma: Study protocol for the development of a core outcome set, a Pediatric Emergency Reserarch Networks (PERN) study

    Trials, Vol. 21, Núm. 1

  2. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial

    BMC Cancer, Vol. 20, Núm. 1

  3. Standardization of Nomenclature for Ocular Tuberculosis–Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop

    Ocular Immunology and Inflammation, Vol. 28, Núm. sup1, pp. 74-84

  4. The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings

    Ocular Immunology and Inflammation, Vol. 28, Núm. sup1, pp. 85-95

  5. Variants of STAR, AMH and ZFPM2/FOG2 may contribute towards the broad phenotype observed in 46,XY DSD patients with heterozygous variants of NR5A1

    International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-18

2019

  1. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304

2018

  1. GATA4 variants in individuals with a 46,XY Disorder of Sex Development (DSD) may or may not be associated with cardiac defects depending on second hits in other DSD genes

    Frontiers in Endocrinology, Vol. 9, Núm. APR

  2. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phiGFBP-1 tests: Systematic review and meta-analysis

    Ultrasound in Obstetrics and Gynecology, Vol. 52, Núm. 4, pp. 442-451

2017

  1. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3